Successfull device feasibility studies with sterna biologicals asthma drug candidates SB010 enables select of optimal nebulizers for late-stage development and commercialization

Marburg, Germany, September 05, 2018 

  • Feasibility studies show excellent data with SB010 across a selection of high efficiency hand-held nebulizers
  • Company well positioned to advance SB010 into late-stage clinical development

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has successfully completed in vitro device feasibility studies with its asthma drug candidate, SB010. These studies support the selection of the most efficient and user-friendly device options for late-stage development and commercialization of SB010.

sterna biologicals prepares for phase IIB clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis

Marburg, Germany, September 05, 2018

  • Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
  • Devices for SB010 in asthma selected, oral formulation work for SB012 in ulcerative colitis (UC) started

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today provided an update on its preparations for phase IIb clinical development of its GATA-3 antagonist drug candidates SB010 and SB012.

sterna biologicals announces data with gata-3 specific dnazyme SB012 to be presented at Digestive Disease Week®

Marburg, Germany, May 29, 2018

  • Further insights and data from Phase 2a trial in ulcerative colitis

Sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that further insights and data from a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its DNAzyme candidate SB012 will be presented at Digestive Disease Week® (DDW) in Washington, DC, June 2-5, 2018.

sterna biologicals presents detailed results from successful phase 2a study with GATA-3 specific DNAzyme formulation SB012 in patients with ulcerative colitis

Marburg, Germany, June 5, 2018

  • Comprehensive data set presented at Digestive Disease Week® in the U.S.
  • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis
  • Further support of GATA-3 antagonism as promising treatment approach for variety of chronic inflammatory diseases

sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that the full data set from the successful SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with the GATA-3 specific DNAzyme formulation SB012, was presented during an oral session on June 5th at Digestive Disease Week® in Washington, DC.

sterna biologicals announces phase IIa data with SB010 published in Respiratory Research

Marburg, Germany, April 19, 2018

  • Investigator initiated study sponsored and funded by DZL (German Center for Lung Research) in patients with moderate to severe eCOPD
  • Primary endpoint and key secondary endpoints met

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that data from a randomized, double-blind, placebo-controlled, multicenter phase IIa trial with SB010 in chronic obstructive pulmonary disease (COPD) patients with eosinophilic airway inflammation have been published in the peer-reviewed medical journal, Respiratory Research[i].